kerostx.com (KROS) Quarterly EPS earnings growth

Symbol and logo of brand Keros Corp (KROS)

Quarterly EPS dynamics demonstrate market confidence in stable leadership advancing research into rare pathologies. Profit growth is based on future sales of anemia and bone disease therapies, as well as partnerships with scientists to study tissue regeneration. The current mark 488.40 indicates the level of the fundamental state of Keros Therapeutics (KROS), confirming the company's development vector.

KROS: Keros Therapeutics, Inc. Year-over-year earnings per one share growth for the last 12 months 07/04/2022 - 11/18/2026

Keros Therapeutics (KROS) - metric breakdowns and financial figures

- share price and expert price forecast:
Initial company analysis:Keros Therapeutics
Flagship merchandise of Keros Corp

Keros Therapeutics (KROS) is scaling its business by patenting high-margin hematological drugs. The current quarterly EPS trend on the GURU.Markets platform reflects the effectiveness of this strategy. This metric measures the percentage change in net income per share, revealing the actual profitability of the business. The growth of this metric confirms the successful monetization of scientific investments. A steady increase in EPS serves as a signal of fundamental stability for long-term investors.

Who Keros Therapeutics competes with

VRTX: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Alnylam Inc. (ALNY)|INSM (Insmed) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months UTHR (United Therapeutics Corporation)|Year-over-year net earnings per share growth for the last 12 months BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth BGM (BGM Group Ltd)|COGT (Cogent Bio) - Year-over-year net earnings per share trend for the last twelve months|Xeris Biopharma - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months ARCT (Arcturus Therapeutics)|ETON: Quarterly EPS earnings growth|Kamada Ltd (KMDA) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Fulcrum Tx|ABEO: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Mereo BioPharma Group (MREO)|Quarterly EPS earnings growth protalix.com (PLX)|Quarterly EPS earnings growth PLRX (Pliant Therapeutics Inc)|Quarterly EPS earnings growth Applied Therapeutics APLT|RNTX - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year gelteq.com (GELS)|AYTU (aytubio.com) - Year-over-year net earnings per share growth for the last 12 months|Chemomab Therapeutics Ltd - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months SRXH|Year-over-year earnings per share growth for the last twelve months PLRZ|Quarterly EPS earnings growth AEZS|Year-over-year earnings per share growth for the last twelve months CYTH (Cyclo Therapeutics, Inc)|Inozyme Pharma - Year-over-year net earnings per share growth for the last 12 months|Reneo Pharmaceuticals, Inc. (RPHM) - Earnings per share growth in annualized terms for the last twelve months|COSCIENS Bio - Quarterly EPS earnings growth